Diazoxide (DrugBank: Diazoxide)
2 diseases| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 13 | Multiple sclerosis/Neuromyelitis optica | 1 |
| 193 | Prader-Willi syndrome | 7 |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2010-023048-34-DE (EUCTR) | 31/08/2011 | 10/05/2011 | A Phase IIa Multicenter Double Blind Study to Evaluate the Efficacy and Safety of low doses of oral Diazoxide for the treatment of Multiple Sclerosis. | A Phase IIa Multicenter Double Blind Study to Evaluate the Efficacy and Safety of low doses of oral Diazoxide for the treatment of Multiple Sclerosis. - NeuroAdvan | Multiple Sclerosis Treatment. MedDRA version: 14.1;Level: PT;Classification code 10063399;Term: Relapsing-remitting multiple sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Product Name: Diazoxide Product Code: Diazoxide INN or Proposed INN: Diazoxide Product Name: Diazoxide Product Code: Diazoxide INN or Proposed INN: Diazoxide | NEUROTEC PHARMA, S.L | NULL | Not Recruiting | Female: yes Male: yes | 99 | Phase 2a | Spain;Germany |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04086810 (ClinicalTrials.gov) | October 15, 2019 | 10/9/2019 | An Open-Label Study of DCCR Tablet in Patients With PWS | An Open-Label Study of Diazoxide Choline Controlled-Release Tablet in Patients With Prader-Willi Syndrome | Prader-Willi Syndrome | Drug: DCCR | Soleno Therapeutics, Inc. | NULL | Not yet recruiting | 4 Years | N/A | All | 105 | Phase 3 | NULL |
| 2 | EUCTR2018-004216-22-GB (EUCTR) | 25/09/2019 | 27/06/2019 | A study to determine the safety of the study drug Diazoxide Choline Controlled-Release Tablet after being given for a long time to patients with the genetic disorder Prader-Willi Syndrome. | An Open-Label, Long-Term Safety and Efficacy Evaluation of Diazoxide Choline Controlled-Release Tablet in Patients with Prader-Willi Syndrome | Hyperphagia associated with Prader-Willi Syndrome (PWS) MedDRA version: 20.0;Level: PT;Classification code 10020710;Term: Hyperphagia;System Organ Class: 10027433 - Metabolism and nutrition disorders;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16] | Product Name: diazoxide choline Product Code: DCCR INN or Proposed INN: Diazoxide choline Other descriptive name: DIAZOXIDE CHOLINE | Soleno Therapeutics UK Ltd. | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 105 | Phase 3 | United States;United Kingdom | ||
| 3 | EUCTR2018-004215-50-GB (EUCTR) | 23/04/2019 | 12/08/2019 | A study to evaluate the effects of a medicine named diazoxide choline in patients with the genetic disorder Prader-Willi syndrome. | A Randomized, Double-Blind, Placebo-Controlled Study of Diazoxide Choline Controlled-Release Tablet (DCCR) in Patients with Prader-Willi Syndrome | Hyperphagia associated with Prader-Willi Syndrome. MedDRA version: 20.0;Level: PT;Classification code 10020710;Term: Hyperphagia;System Organ Class: 10027433 - Metabolism and nutrition disorders ;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16] | Soleno Therapeutics UK Ltd. | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 105 | Phase 3 | United States;United Kingdom | |||
| 4 | NCT03714373 (ClinicalTrials.gov) | October 1, 2018 | 27/9/2018 | Open-Label Extension Study of Diazoxide Choline in Patients With Prader-Willi Syndrome | An Open-Label, Long-Term Safety Evaluation of Diazoxide Choline Controlled-Release Tablet in Patients With Prader-Willi Syndrome | Prader-Willi Syndrome | Drug: DCCR | Soleno Therapeutics, Inc. | NULL | Active, not recruiting | 4 Years | N/A | All | 105 | Phase 3 | United States;United Kingdom |
| 5 | NCT03440814 (ClinicalTrials.gov) | May 9, 2018 | 13/2/2018 | A Study of Diazoxide Choline in Patients With Prader-Willi Syndrome | A Randomized, Double-Blind, Placebo-Controlled Study of Diazoxide Choline Controlled-Release Tablet (DCCR) in Patients With Prader-Willi Syndrome | Prader-Willi Syndrome | Drug: DCCR;Drug: Placebo for DCCR | Soleno Therapeutics, Inc. | NULL | Completed | 4 Years | N/A | All | 127 | Phase 3 | United States;United Kingdom |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 6 | NCT02893618 (ClinicalTrials.gov) | July 2017 | 30/8/2016 | A 5 Treatment Period Pharmacokinetic Study Evaluating Dose Proportionality and Food Effects of Diazoxide Choline Controlled-Release Tablet (DCCR) | A 5 Treatment Period Crossover Pharmacokinetic Study Evaluating Dose Proportionality and Food Effects of Diazoxide Choline Controlled-Release Tablet (DCCR) | Prader-Willi Syndrome | Drug: Diazoxide choline controlled-release tablet | Essentialis, Inc. | NULL | Not yet recruiting | 18 Years | 65 Years | Both | 32 | Phase 2 | NULL |
| 7 | NCT02034071 (ClinicalTrials.gov) | April 2014 | 8/1/2014 | Clinical Study of Diazoxide Choline Controlled-Release Tablet (DCCR) in Patients With Prader-Willi Syndrome | A Dose Titration Study of Diazoxide Choline Controlled-Release Tablet (DCCR) in Patients With Prader-Willi Syndrome With a Double-Blind, Placebo-Controlled, Randomized Withdrawal Extension | Prader-Willi Syndrome | Drug: DCCR;Drug: Placebo | Essentialis, Inc. | NULL | Completed | 10 Years | 22 Years | Both | 13 | Phase 1;Phase 2 | United States |